 |
|
SATURDAYNovember 8SESSION 43:25 – 3:40 |
Jerry Tan High quality randomized clinical trials have demonstrated the efficacy in acne of the following hormonal combination preparations: ethinyl estradiol 0.035 mg/ norgestimate (Tri-Cyclen®), ethinyl estradiol 20 mg / levonorgestrel 100 mg (Alesse®), and ethinyl estradiol 0.035 mg / cyproterone acetate 2 mg (Diane-35®). Unfortunately, no comparative randomized controlled trials exist between these agents. The Canadian Acne Epidemiological Survey was developed to evaluate demographic, epidemiological and outcomes issues of interest in acne research. This was performed by development of a patient questionnaire and clinical evaluation forms for completion at baseline, and months 2, 6 and 12. The questionnaire comprised fields relevant to basic demographics, medical symptoms and co-existent morbidity, family history, prior treatments and outcomes, and patient expectations. After ethics review approval of the protocol and informed consent, six Canadian dermatology sites initiated patient recruitment of consecutive acne referrals in the fourth quarter of 2002. Baseline data on the responses and preferences of female patients in this survey to hormonal therapy are herein presented. This cross-sectional analysis demonstrated that female acne patients previously treated with hormones ranked Diane-35 as foremost in effectiveness. This epidemiological survey provides evidence that Diane-35 may be the most effective of the hormonal agents currently approved in Canada for treatment of acne in women. Declaration: This project was partially funded by Berlex, Roche, Stiefel and Dermik. Lead investigator, Canadian Acne Epidemiological Survey, University of Western Ontario, Windsor, Ontario, Canada |